NBSE — NeuBase Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: NeuBase Therapeutics Reports Q3 Loss Per Share $0.18
Brief: Neubase Therapeutics Appoints William Mann As Chief Operating Officer
Brief: Neubase Therapeutics Reports Q2 Loss Per Share Of $0.26
NeuBase Therapeutics slides on deep-discounted stock deal
Brief: Neubase Therapeutics Announces Proposed Public Offering Of Common Stock
Brief: Neubase Therapeutics Reports Q1 Loss Per Share Of $0.26
Brief: NeuBase Therapeutics Receives Notification Of Deficiency From Nasdaq Related To Delayed Quarterly Report On Form 10-Q
Brief: Neubase Therapeutics Says At Sept. 30, 2019, Co Had Cash And Cash Equivalents Of About $10.3 Mln
Brief: NeuBase Therapeutics Files For Non-Timely 10-K
Brief: Neubase Therapeutics Announces Issuance Of A Foundational Patent
Brief: Neubase says Files Prospectus Related To Resale By Selling Stockholders
Brief: Shawn Milemore Titcomb And Jennifer Bove Titcomb Joint Living Trust Report 5.05% Pasive Stake In Neubase Therapeutics
Brief: NeuBase Therapeutics Says Qtrly Loss Per Share $0.40
Brief: Dietrich Stephan Reports 34.3% Stake In Neubase Therapeutics Inc As Of July 12
Brief: Shivaji Thadke Reports 6.0% Passive Stake In Neubase Therapeutics Inc As Of July 12
OHR Pharma shares jump as merger with NeuBase closes
Brief: OHR Pharmaceutical Announces Stockholder Approval Of Merger Agreement With Neubase Therapeutics
OHR Pharma shares soar as investors approve merger with NeuBase
NASDAQ RESUMED